Five Reasons Why GSK Spinning Off Consumer Health Wouldn't Be Easy
This article was originally published in The Rose Sheet
Executive Summary
GSK once again provided grist to the stock market rumor mill recently with reports of its chairman talking to major shareholders about the possibility of splitting up the company. But there are reasons to doubt whether talks would lead to action any time soon.
You may also be interested in...
GSK Gains Clarity For Pharma Focus Through Novartis Consumer JV Buy
GSK removed some uncertainty about how much it could invest in pharma R&D and business development by purchasing Novartis' share of the firms' Consumer Healthcare Joint Venture. Now it can more accurately allocate capital as it prepares for battle in HIV and braces for Advair generics.
GSK Bags Barron As R&D Boss As Vallance Joins UK Government
UK pharma giant GlaxoSmithKline has nabbed a high-profile figure from Google's Calico to head up its research efforts. Barron's oncology pedigree from his time at Roche suggests that cancer is again a core area for GSK.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.